Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences executive Johanna Mercier reported open-market sales of 3,000 shares of Gilead common stock. The transactions occurred on June 15, 2026 at prices ranging from $122.79 to $125.40 per share, as described in the footnotes.
The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. After the transactions, Mercier directly holds 124,234 shares of Gilead common stock, according to the reported post-transaction balance.
Gilead Sciences Chief Financial Officer sells shares under trading plan
Gilead Sciences CFO Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at $125.40 per share. After the sale, he directly holds 171,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for proposed sales of 9,000 common shares by Andrew Dickinson. The filing lists three sales dates — 03/16/2026, 04/15/2026, and 05/15/2026 — each for 3,000 shares, with dollar amounts shown per sale.
Morgan Stanley Smith Barney LLC filed a Rule 144 notice relating to 3,000 shares of Common Stock of GILD (listed as performance shares dated 02/04/2025) that are proposed to be sold by the issuer under Rule 144. The filing also lists recent sales by Johanna Mercier: 28,000, 3,000, and 3,000 shares on 05/15/2026, 04/15/2026, and 03/16/2026, respectively, with stated proceeds for each sale.
Gilead Sciences Chief Medical Officer Dietmar Berger reported routine equity compensation activity. On June 10, 2026, he exercised 533 restricted stock units, converting them into the same number of Gilead common shares at an exercise price of $0.00 per share.
To cover associated tax obligations, 263 common shares were disposed of at $121.48 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 19,252 shares of common stock and 46,928 restricted stock units, which continue to vest over a four-year schedule.
Gilead Sciences EVP and General Counsel Keeley M. Cain Wettan reported routine equity compensation activity. On June 10, 2026, 589 shares of common stock were acquired through a derivative exercise/conversion of restricted stock units at $0.00 per share.
On the same date, 283 shares of common stock were disposed of in a tax-withholding disposition at $121.48 per share to cover obligations tied to this equity event. After these transactions, the insider directly holds 5,643 shares of common stock and 19,997 restricted stock units, which vest over a four-year schedule.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported routine equity compensation activity. On June 10, 2026, he exercised restricted stock units covering 2,796 shares of common stock at a conversion price of $0.00 per share.
To cover tax obligations, 1,341 shares of common stock were disposed of as a tax-withholding transaction at $121.48 per share, rather than through an open-market sale. Following these transactions, he holds 175,987 shares of Gilead common stock directly and 27,851 restricted stock units, which vest over a four-year schedule.
Gilead Sciences Chief Commercial and Corporate Affairs Officer Johanna Mercier exercised restricted stock units and had shares withheld for taxes. On this date, 2,796 restricted stock units converted into 2,796 shares of common stock, while 1,341 shares were disposed of to cover tax obligations.
After these transactions, Mercier directly held 128,575 shares of common stock and 27,851 restricted stock units. The RSUs represent contingent rights to receive one share of common stock each and vest over four years, with 25% on the first anniversary of grant and the remainder vesting quarterly at 6.25% until fully vested.
Gilead Sciences Chairman & CEO Daniel O'Day reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised derivative awards covering 8,779 restricted stock units that convert into the same number of common shares at a price of $0.0000 per share. To cover tax obligations, 4,213 common shares were disposed of at $121.48 per share through a tax-withholding arrangement, not an open-market sale.
Following these transactions, O'Day directly holds 626,346 shares of common stock and 92,080 restricted stock units. The RSUs vest over four years, with 25% vesting on the first anniversary of grant and the remaining 75% vesting 6.25% each quarter until fully vested.
Gilead Sciences Chairman & CEO Daniel O'Day reported open-market sales of 15,000 shares of Common Stock. The trades took place on June 1, 2026 in three transactions at prices around $131 per share. Footnotes state these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, indicating the timing was scheduled in advance rather than discretionary.